- Home
- Publications
- Publication Search
- Publication Details
Title
Dapagliflozin in patients with type 2 diabetes mellitus
Authors
Keywords
-
Journal
Therapeutic Advances in Endocrinology and Metabolism
Volume 6, Issue 1, Pages 29-41
Publisher
SAGE Publications
Online
2014-11-29
DOI
10.1177/2042018814558243
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes
- (2014) Luca De Nicola et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Diagnosis and Treatment of Diabetic Kidney Disease
- (2014) Aidar R. Gosmanov et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study
- (2014) Linong Ji et al. CLINICAL THERAPEUTICS
- Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin
- (2014) S. Grandy et al. DIABETES OBESITY & METABOLISM
- The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors
- (2014) Theodosios D Filippatos et al. Expert Opinion on Drug Metabolism & Toxicology
- Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years
- (2014) S. Grandy et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
- (2014) Raymond V. Oliva et al. Journal of the American Society of Hypertension
- Dapagliflozin: Glucuretic action and beyond
- (2014) Pitchai Balakumar et al. PHARMACOLOGICAL RESEARCH
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease
- (2014) Stefano Ballestri WORLD JOURNAL OF GASTROENTEROLOGY
- Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus
- (2014) Timothy P. Reilly et al. Diabetes Therapy
- Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
- (2014) Krzysztof Strojek et al. Diabetes Therapy
- Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
- (2013) John P.H. Wilding ANNALS OF INTERNAL MEDICINE
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
- (2013) Clifford J Bailey et al. BMC Medicine
- Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands
- (2013) Heleen G. M. van Haalen et al. CLINICAL DRUG INVESTIGATION
- Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
- (2013) Sreeneeranj Kasichayanula et al. CLINICAL PHARMACOKINETICS
- Estimating the Population Prevalence of Diagnosed and Undiagnosed Diabetes
- (2013) A. Leong et al. DIABETES CARE
- Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
- (2013) Serge A. Jabbour et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2014
- (2013) DIABETES CARE
- Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis
- (2013) S. Goring et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
- (2013) J. P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin
- (2013) Sunder Mudaliar et al. Diabetes Technology & Therapeutics
- Urinary tract infections in patients with diabetes treated with dapagliflozin
- (2013) Kristina M. Johnsson et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin
- (2013) Kristina M. Johnsson et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Medical Management and Strategies to Prevent Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus
- (2013) Mae Sheikh-Ali et al. POSTGRADUATE MEDICINE
- Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
- (2013) Akira Imamura et al. Diabetes Therapy
- Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin
- (2012) Sreeneeranj Kasichayanula et al. ADVANCES IN THERAPY
- The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus
- (2012) Sreeneeranj Kasichayanula et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Simultaneous oral therapeutic and intravenous 14 C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin
- (2012) David W. Boulton et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
- (2012) J. Rosenstock et al. DIABETES CARE
- Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin
- (2012) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
- (2012) Ö. Ljunggren et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range
- (2012) C. J. Bailey et al. DIABETES OBESITY & METABOLISM
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- FDA rejects novel diabetes drug over safety fears
- (2012) Talha Khan Burki LANCET
- Dapagliflozin: A Novel Sodium-Glucose Cotransporter Type 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
- (2012) Niren K. Shah et al. PHARMACOTHERAPY
- Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
- (2012) Christine Clar et al. BMJ Open
- Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
- (2012) Jean Whaley et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study
- (2011) Sreeneeranj Kasichayanula et al. CLINICAL THERAPEUTICS
- Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?
- (2011) Niki Katsiki et al. Current Vascular Pharmacology
- Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
- (2011) M. A. Nauck et al. DIABETES CARE
- Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects
- (2011) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
- (2011) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
- (2011) K. Strojek et al. DIABETES OBESITY & METABOLISM
- Current treatment for nonalcoholic fatty liver disease
- (2011) Niki Katsiki et al. EXPERT OPINION ON PHARMACOTHERAPY
- Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
- (2011) Abd A. Tahrani et al. Diabetes Therapy
- Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study
- (2011) Glenn F. Carlson et al. Diabetes Therapy
- Obesity and Arterial Compliance Alterations
- (2010) Alexander Seifalian et al. Current Vascular Pharmacology
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
- (2010) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
- (2010) L. Zhang et al. DIABETES OBESITY & METABOLISM
- SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
- (2010) V. Vallon et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Sodium-glucose transporter-2 inhibition as an antidiabetic therapy
- (2010) E. Ferrannini NEPHROLOGY DIALYSIS TRANSPLANTATION
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
- In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
- (2009) M. Obermeier et al. DRUG METABOLISM AND DISPOSITION
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now